Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Omega-3
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Change in Omega 3 Index in Healthy Adults with OmeGo or a Standard Omega-3 Oil Supplement
Details : Undisclosed
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
January 30, 2025
Lead Product(s) : Omega-3
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Omega-3
Therapeutic Area : Sleep
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
January 10, 2025
Lead Product(s) : Omega-3
Therapeutic Area : Sleep
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Omega-3
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : McGill University | Netherlands Open University | Massachusetts General Hospital | Ekhagastiftelsen | AquaOmega | Lipid Analytical Laboratories | Mitacs
Deal Size : Inapplicable
Deal Type : Inapplicable
Dietary Counselling Plus Omega-3 Supplementation in the Treatment of Generalized Anxiety Disorder
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
October 10, 2022
Lead Product(s) : Omega-3
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : McGill University | Netherlands Open University | Massachusetts General Hospital | Ekhagastiftelsen | AquaOmega | Lipid Analytical Laboratories | Mitacs
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Omega-3
Therapeutic Area : Musculoskeletal
Study Phase : Undisclosed
Sponsor : Evonik Operations GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy of a Dietary Ingredient Combination With Omega-3 for Joint Function
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
March 15, 2022
Lead Product(s) : Omega-3
Therapeutic Area : Musculoskeletal
Highest Development Status : Undisclosed
Sponsor : Evonik Operations GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Omega-3,Omega 6
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Nuvothera
Deal Size : Undisclosed
Deal Type : Licensing Agreement
DS Biopharma and Nuvothera Enter Option and License Agreement for EPADILIN®
Details : Under the terms of the agreement Nuvothera has acquired an option to exclusively licence rights to develop and commercialise EPADILIN® in the United States.
Product Name : Epadilin
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Undisclosed
March 18, 2021
Lead Product(s) : Omega-3,Omega 6
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Nuvothera
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Omega-3
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Acasti Pharma Provides Update on TRILOGY 1 and TRILOGY 2 Phase 3
Details : Acasti Pharma plans to seek FDA guidance prior to unblinding TRILOGY 2 data, which is expected to delay reporting of TRILOGY 2 topline results until calendar Q3, 2020.
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
October 02, 2020
Lead Product(s) : Omega-3
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
High Dose Omega 3 in People at Risk for Dementia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
April 24, 2019
Lead Product(s) : Omega-3
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Samuel Fortin, SFC pharma and associate professor UQAR
Deal Size : Inapplicable
Deal Type : Inapplicable
MaxSimil and Vitamin K2: Determining Their Bioavailability
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
April 01, 2019
Lead Product(s) : Omega-3
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Samuel Fortin, SFC pharma and associate professor UQAR
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Omega-3
Therapeutic Area : Musculoskeletal
Study Phase : Undisclosed
Sponsor : KU Leuven | VISTA-Life | Nestle Health Sciences SA
Deal Size : Inapplicable
Deal Type : Inapplicable
Exercise and Nutrition for Healthy AgeiNg
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
August 28, 2018
Lead Product(s) : Omega-3
Therapeutic Area : Musculoskeletal
Highest Development Status : Undisclosed
Sponsor : KU Leuven | VISTA-Life | Nestle Health Sciences SA
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Omega-3
Therapeutic Area : Ophthalmology
Study Phase : Undisclosed
Sponsor : Centre for Contact Lens Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of an Oral Supplement Containing Omega-3 and Omega-6 on Dry Eye Symptoms
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
August 29, 2017
Lead Product(s) : Omega-3
Therapeutic Area : Ophthalmology
Highest Development Status : Undisclosed
Sponsor : Centre for Contact Lens Research
Deal Size : Inapplicable
Deal Type : Inapplicable